Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2023 CLL
ASH 2023 - CLL
Long-Term Outcomes of Ibrutinib Therapy in CLL
ASH 2023 - CLL
Long-term follow-up data of a phase 2 study confirmed the extended prognosis of ibrutinib-treated patients with CLL, particularly those with TP53 alterations.
Read More ›
Extended Follow-up of ALPINE Study Confirmed Superior PFS Benefit of Zanubrutinib Versus Ibrutinib in R/R CLL/SLL
ASH 2023 - CLL
Longer follow-up data of the randomized, phase 3 ALPINE study confirmed PFS benefit and more favorable cardiac safety profile of zanubrutinib compared to ibrutinib therapy in patients with R/R CLL/SLL, with emergence of no new safety signals.
Read More ›
Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab in Relapsed/Refractory CLL
ASH 2023 - CLL
Results of the phase 2 CLL2-BAAG trial showed that MRD-guided triple combination therapy of acalabrutinib, venetoclax and obinutuzumab yielded better efficacy outcomes, deeper remission, and achievement of uMRD in patients with R/R CLL.
Read More ›
Phase 1/2 Study Data of Combination Sonrotoclax (BGB-11417) Plus Zanubrutinib in Treatment-Naïve CLL/SLL
ASH 2023 - CLL
Data from an ongoing, first-in-human phase 1/2 study suggests that combination sonrotoclax (160 mg and 320 mg) plus zanubrutinib therapy was well tolerated and showed encouraging anti-leukemic activity in patients with treatment-naive CLL/SLL.
Read More ›
Page 2 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us